Metabolic Syndrome Gene-Edited Cell Lines for Drug Discovery

Metabolic syndrome (MetS) affects approximately 25% of the global adult population, according to the World Health Organization (WHO). It is defined by a cluster of conditions including central obesity, hyperglycemia, dyslipidemia, and hypertension. MetS increases the risk of type 2 diabetes by 5-fold and cardiovascular disease by 2-fold. The prevalence rises with age, affecting over 40% of individuals aged 60 and older. The National Cancer Institute (NCI) highlights that MetS is also linked to increased risk of certain cancers, such as colorectal and breast cancer, though 5-year survival data by stage is not directly applicable. Key risk factors include sedentary lifestyle, high-calorie diet, genetic predisposition, and hormonal changes.

Metabolic syndrome is an ideal model for mechanistic studies due to its multifactorial nature and the availability of large public datasets like the UK Biobank and Framingham Heart Study. Subtypes include insulin-resistant, inflammatory, and lipodystrophic phenotypes. Open questions include the molecular crosstalk between adipose tissue, liver, and muscle, and the role of epigenetic modifications. Gene-edited cell models enable precise dissection of these pathways.

While metabolic syndrome is not a cancer, its pathways overlap with oncogenic signaling. Key pathways include:

• • Insulin/IGF-1 signaling: Hyperinsulinemia activates PI3K/AKT and MAPK pathways, promoting cell growth.
• • Adipokine signaling: Dysregulation of leptin and adiponectin affects inflammation and insulin sensitivity.
• • Inflammatory pathways: Activation of NF-kB and JNK pathways due to cytokine release from adipose tissue.
• • Lipid metabolism: Altered PPAR signaling and SREBP activation lead to lipotoxicity.

Data from COSMIC and ClinVar.

• • Insulin receptor (IR) / IRS1 / PI3K / AKT: Central to glucose uptake.
• • Leptin receptor (LEPR) / JAK2 / STAT3: Regulates appetite and energy expenditure.
• • PPARγ / RXR: Controls adipogenesis and lipid storage.
• • AMPK: Master regulator of energy homeostasis, often suppressed in MetS.

Organoids derived from human adipose or liver tissue provide 3D architecture and cell-cell interactions, better mimicking in vivo metabolism.

• • High-fat diet (HFD) induced obesity models in mice: recapitulate human MetS.
• • Genetically engineered mouse models (GEMM): ob/ob (leptin deficiency), db/db (leptin receptor deficiency).
• • Patient-derived xenografts (PDX) for cancer-MetS interactions.

CRISPR-Cas9 technology enables creation of isogenic cell lines with precise genetic modifications. For example, PPARG knockout in HepG2 cells models insulin resistance, while IRS1 knock-in with common polymorphisms allows functional studies. Commercially available, sequence-verified models accelerate research by providing consistent, validated tools. These models are essential for studying gene function in a controlled genetic background.

Knockout of FTO in 3T3-L1 cells reduces adipogenesis, validating its role in obesity. Knock-in of PPARG variants in HepG2 cells reveals altered lipid accumulation. These models enable high-throughput functional screens.

Isogenic pairs (e.g., wild-type vs. IRS1 mutant) are used to screen insulin sensitizers. Resistance to metformin can be modeled by knocking out AMPK subunits, identifying compensatory pathways.

CRISPR synthetic lethality screens in isogenic cell lines identify genes essential for survival under metabolic stress. For example, knockout of SCD1 in lipotoxic conditions reveals new therapeutic targets.